The JAK1/JAK2 inhibitor ruxolitinib received approval for use in primary myelofibrosis (MF), and then for polycythemia vera (PV), improving disease-related symptoms but not preventing MF or progression to acute myeloid leukemia [5]. The gene discussed is JAK1; the disease is acquired polycythemia vera.